

# Herpes Zoster (Shingles) Pipeline Report, 2023-Planned Drugs by Phase, Mechanism of Action, Route of Administration, Type of Molecule, Market Trends, Developments, and Companies

https://marketpublishers.com/r/HE0B53E854D6EN.html

Date: February 2023

Pages: 130

Price: US\$ 2,100.00 (Single User License)

ID: HE0B53E854D6EN

### **Abstracts**

Herpes Zoster (Shingles) Pipeline Report is a comprehensive report on the pre-clinical and clinical stage pipeline candidates under development as of H1 2023. For each of the Herpes Zoster (Shingles) pipeline candidate, details of leading companies, phase of development, mechanism of action, route of administration, molecule type, and other critical information is provided. In addition, recent Herpes Zoster (Shingles) market trends, developments, and other market updates are provided in the Herpes Zoster (Shingles) pipeline study.

The global Herpes Zoster (Shingles) industry is characterized by a robust pipeline. The report estimates a promising pipeline for Herpes Zoster (Shingles) between 2023 and 2030. Further, emerging companies play an important role in the global share of the Herpes Zoster (Shingles) pipeline. It is developed through intense primary and secondary research including discussions with pharmaceutical company executives and members of industry associations and other industry stakeholders.

Overview of Herpes Zoster (Shingles) Drug Development Pipeline: 2023 Update The Herpes Zoster (Shingles) condition has one of the most promising pipelines with the presence of a large number of pharmaceutical companies. Amidst significant unmet market potential for Herpes Zoster (Shingles), several small and large-scale companies are investing in advancing their pipeline candidates into advanced phases.

The current Herpes Zoster (Shingles) pipeline study examines the state of the drug pipeline and provides insights into the global vitiligo industry. A complete pipeline review



of the current treatments and therapies being developed for Herpes Zoster (Shingles), Data, and insights into pipeline candidates including a detailed overview of the highlighted target and drug characteristics, companies, and developments are included.

Looking Ahead: 2023 Herpes Zoster (Shingles) Pipeline Analysis and Outlook This quarterly updated report provides data and critical insights into the current pipeline of therapeutic candidates in development with the potential to address Herpes Zoster (Shingles). The current status of each of the Herpes Zoster (Shingles) drug pipeline candidates is provided in the study. In addition, developing and licensing/partner companies, originators, alternative drug names, special status, phase, trial details, route, target, molecule type, and others are provided in the study.

## Preclinical Herpes Zoster (Shingles) Pipeline Drugs

The global vitiligo therapeutic pipeline is characterized by a significant number of drug candidates in the preclinical drug discovery and research phases. Driven by robust market growth prospects for Herpes Zoster (Shingles) therapeutic drugs, a large number of companies are investing in the preclinical Herpes Zoster (Shingles) pipeline. The report provides the current status and other developments of each drug candidate.

### Clinical Phase Herpes Zoster (Shingles) Pipeline Drugs

The report showcases the pipeline candidates currently underway focusing on medications that are in Phase I, Phase I/II, Phase II, Phase II/III, and Phase III stages of development. The chapter presents the number of projects in clinical development by pipeline phase.

### Herpes Zoster (Shingles) Clinical Trials Landscape

The report provides in-depth information on the Herpes Zoster (Shingles) clinical trials of each pipeline product. To support pharmaceutical companies to understand the suitable countries for clinical trials, study types, and other parameters to minimize complexity and increase success rates, the report offers details of all potential clinical trials.

### Herpes Zoster (Shingles) companies in Pipeline

Amidst growth in R&D investment, pharmaceutical companies increasingly emphasize strengthening their pipeline product portfolio to ensure time-efficient drug developments. The Herpes Zoster (Shingles) pipeline assessment report provides details of drug companies, originators, licensing and collaborating partners, and others involved in the Herpes Zoster (Shingles) pipeline industry.



### Market Developments

The report offers recent market news and developments in the Herpes Zoster (Shingles) markets. To support companies developing innovative therapies in both the preclinical and clinical stages of development, the chapter provides recent deals, mergers, and development news in the industry.

### Scope of the Report

An introduction to the Herpes Zoster (Shingles) disease, diagnosis, and therapeutic snapshots including available options and the companies involved in the industry Analysis of Herpes Zoster (Shingles) drugs in the preclinical phase of development including discovery and research

Most promising Herpes Zoster (Shingles) drugs in the clinical stage of development including phase 1, phase 2, and phase 3

Leading companies investing in the Herpes Zoster (Shingles) drug development pipeline

Herpes Zoster (Shingles) pipeline drug details-

Drug name and alternative names

Current status of the pipeline candidate

Route of administration

Mechanism of Action

Molecule type

Clinical trials completed and ongoing

Companies involved in the development, technology providers, licensing/collaborations, etc.

Business profiles of leading Herpes Zoster (Shingles) companies Recent Herpes Zoster (Shingles) market news and developments



### **Contents**

### 1. HERPES ZOSTER (SHINGLES) PIPELINE ASSESSMENT, 2023

- 1.1 Herpes Zoster (Shingles) Pipeline Snapshot
- 1.2 Companies investing in the Herpes Zoster (Shingles) industry

# 2 LOOKING AHEAD: OUTLOOK OF THE GLOBAL HERPES ZOSTER (SHINGLES) PIPELINE FROM 2023 TO 2030

- 2.1 Herpes Zoster (Shingles) Drugs by Phase of Development
- 2.2 Herpes Zoster (Shingles) Drugs by Mechanism of Action
- 2.3 Herpes Zoster (Shingles) Drugs by Route of Administration
- 2.4 Herpes Zoster (Shingles) Drugs by New Molecular Entity
- 2.5 Herpes Zoster (Shingles) Drugs by Companies, Universities, and Institutes

# 3. DRUG PROFILES OF HERPES ZOSTER (SHINGLES) PRECLINICAL PIPELINE CANDIDATES

- 3.1 Current Status of Herpes Zoster (Shingles) Drug Candidates, 2023
- 3.2 Preclinical Herpes Zoster (Shingles) Drug Snapshots

# 4. DRUG PROFILES OF HERPES ZOSTER (SHINGLES) CLINICAL PIPELINE CANDIDATES

- 4.1 Current Status of Herpes Zoster (Shingles) Drug Candidates, 2023
- 4.2 Herpes Zoster (Shingles) Drugs in Development- Originator/Licensor
- 4.3 Herpes Zoster (Shingles) Drugs in Development- Route of Administration
- 4.4 Herpes Zoster (Shingles) Drugs in Development- New Molecular Entity (NME)

### 5. HERPES ZOSTER (SHINGLES) CLINICAL TRIALS ANALYSIS

- 5.1 Preclinical Trial Snapshots
- 5.2 Phase 1 Clinical Trial Snapshots
- 5.3 Phase 2 Clinical Trial Snapshots
- 5.4 Phase 3 Clinical Trial Snapshots

# 6. HERPES ZOSTER (SHINGLES) PIPELINE COMPANIES ACTIVE IN 2023



- 6.1 Leading Herpes Zoster (Shingles) companies investing in new drug development
  - 6.1.1 Company Business Description
  - 6.1.2 Company Pipeline snapshot
- 6.2 Leading Herpes Zoster (Shingles) Universities/Institutes researching drug development

# 7. HERPES ZOSTER (SHINGLES) MARKET NEWS AND DEVELOPMENTS

- 7.1 Recent Herpes Zoster (Shingles) Developments
- 7.2 Herpes Zoster (Shingles) Pipeline News

#### 8. APPENDIX

- 8.1 Sources and Research Methodology
- 8.2 Customization options
- 8.3 Legal Disclaimer



### I would like to order

Product name: Herpes Zoster (Shingles) Pipeline Report, 2023- Planned Drugs by Phase, Mechanism of

Action, Route of Administration, Type of Molecule, Market Trends, Developments, and

Companies

Product link: <a href="https://marketpublishers.com/r/HE0B53E854D6EN.html">https://marketpublishers.com/r/HE0B53E854D6EN.html</a>

Price: US\$ 2,100.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/HE0B53E854D6EN.html">https://marketpublishers.com/r/HE0B53E854D6EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970